Phathom Pharmaceuticals (PHAT) Stock Statistics & Valuation Metrics

Phathom Pharmaceuticals has a market cap or net worth of $323.94M. The enterprise value is ―.

Phathom Pharmaceuticals has 69,814,120 shares outstanding. The number of shares has decreased by -2.65% in one year.

Phathom Pharmaceuticals’s return on equity (ROE) is 1.32 and return on invested capital (ROIC) is -94.67%.

The current PE Ratio of Phathom Pharmaceuticals is -1.53. Phathom Pharmaceuticals’s PEG ratio is -0.36.

In the last 12 months, Phathom Pharmaceuticals had revenue of 55.25M and earned -334.33M in profits. Earnings per share was -5.29.

In the last 12 months, operating cash flow was -282.68M and capital expenditures 35.00K, giving a free cash flow of -282.66M billion.

Phathom Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Phathom Pharmaceuticals upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.

Phathom Pharmaceuticals as a current ratio of 4.20, with Debt / Equity ratio of -60.16%

In the past 12 months, Phathom Pharmaceuticals has paid 0.00 in taxes.

Phathom Pharmaceuticals EV to EBITDA ratio is -1.60, with an EV/FCF ratio of -1.56.

Phathom Pharmaceuticals has $212.31M in cash and marketable securities with $203.56M in debt, giving a net cash position of -$8.75M billion.

Gross margin is 86.23%, with operating margin of -502.18%, and net profit margin of -605.09%.

The average price target for Phathom Pharmaceuticals is $19.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy